Chinese Society of Clinical Oncology Breast Cancer(CSCO BC)guidelines in 2022:stratification and classification

摘要

In April 2017,the first edition Chinese Society of Clinical Oncology Breast Cancer(CSCO BC)guidelines were released.These guidelines were based on medical evidence,as well as the accessibility and cost effectiveness of various anticancer drugs in China.The CSCO BC guidelines include regimens with a high level of evidence,good product accessibility and high consistent consensus among Chinese experts as level I recommendations.Regimens with a high level of evidence but poor product accessibility or expert consensus are included as level II recommendations.